Roche Holding is no longer publicly traded under ROCHE. The ticker stopped returning market quotes on Oct 20, 2026, which usually means the company was delisted, acquired or taken private.
Price history
Roche Holding (ROCHE) is a Health Care company in the Europe. Latest news and coverage below.
About Roche Holding
F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.
- Headquarters
- Chandler, Arizona From SEC filings, Oct 2026
Recent News (20)
-
Roche puts future German investments 'on hold' Roche puts future German investments 'on hold' Reuters
-
Roche, Hansoh ink cancer drug deal (RHHBF:OTCMKTS) Roche, Hansoh ink cancer drug deal (RHHBF:OTCMKTS) Seeking Alpha
-
KRAS Inhibitors Market is Set for Expansion During the Forecast Period (2026-2036) Supported by Emerging Therapies Targeting Diverse KRAS Mutations | DelveInsight The KRAS inhibitors market is expected to experience strong growth, driven by rising cancer incidence, improved treatment access, and a robust pipeline consisting of therapies such as Divarasib (RG633…
-
Roche to unveil lung, breast cancer data at ESMO 2026 Roche to unveil lung, breast cancer data at ESMO 2026 Reuters
-
Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio Basel, 19 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data, including two late-breaking abstracts, across lung, breast and other cancers at the 2026 European Society for Medical…
-
-
Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics Reuters
-
Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases SANTA BARBARA, Calif., Oct. 13, 2026 /PRNewswire/ -- Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona's investigational RNAi …
-
Analog devices chair & CEO Vincent Roche sells $3.97m in stock
Analog devices chair & CEO Vincent Roche sells $3.97m in stock
-
-
Gen Digital appoints Talbott Roche to board of directors
Gen Digital appoints Talbott Roche to board of directors
-
-
-
-
-
-
-
-
-
More Health Care stocks
- BMY Bristol Myers Squibb
- JNJ Johnson & Johnson
- LLY Lilly (Eli)
- MRK Merck & Co.
- PFE Pfizer
- VTRS Viatris
- ZTS Zoetis
- A Agilent Technologies